2023 Annual Meeting | C75 - Myelin Oligodendrocyte Glycoprotein Antibody Disorders (MOGAD)

Date Monday 04/24/23

Time 07:00 AM - 09:00 AM EST Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Brenda L. Banwell, MD, FAAN

Topic(s) Multiple Sclerosis

Learning Objectives Participants will be presented with recently published international consensus diagnostic criteria for MOGAD, and details on laboratory testing for MOG-IgG. Clinical features, disease course, and current therapeutic strategies will be reviewed. MRI findings in MOGAD patients, as well as clues pointing towards other conditions in the differential of MOGAD will be highlighted. Attendees will be provided an up-to-date review of the evolving landscape of MOGAD in both children and adults.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Advanced

Recommended Audience Fellow, Resident, Specialist Neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Didactic

Event Timeline
07:00 AM - 07:05 AM EST	Introduction	Welcome and Introduction Brenda L. Banwell, MD, FAAN
07:05 AM - 07:50 AM EST	Speaker	MOGAD Diagnostic Criteria Brenda L. Banwell, MD, FAAN
07:50 AM - 08:20 AM EST	Speaker	Clinical Features and Management of MOGAD Jacqueline Palace
08:20 AM - 08:50 AM EST	Speaker	Imaging Features of MOGAD and Differential Eoin P. Flanagan, MBBCh, FAAN
08:50 AM - 09:00 AM EST	Discussion	Questions and Answers Brenda L. Banwell, MD, FAAN

Faculty Disclosures
Brenda L. Banwell, MD, FAAN	Dr. Banwell has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Banwell has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Banwell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Banwell has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Banwell has received research support from National MS Society. The institution of Dr. Banwell has received research support from NIH.
Eoin P. Flanagan, MBBCh, FAAN	The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from Viela Bio. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities.
Jacqueline Palace	Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck Serono, Medimmune, Argenx, Janssen, AMgen, UCB, Roche, Novartis, Amplo, Alexion, . Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx, Sanofi. Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Roche, UCB, Alexion, Amgen. Dr. Palace has stock in Astra Zenica. The institution of Dr. Palace has received research support from Roche, AMPLO, Alexion, UCB,. argenx, amgen. Dr. Palace has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��